Triamcinolone acetonide is a potent, intermediate-acting synthetic glucocorticoid with anti-inflammatory, anti-allergic, and immunosuppressive properties. It is approximately 8-10 times more potent than hydrocortisone. The 10mg strength is typically used for intramuscular, intra-articular, or intralesional administration for systemic or localized effects.
Adult: Dose is highly individualized. **Intramuscular:** 40-80 mg as a single dose, repeated at intervals of 1-4 weeks as needed. **Intra-articular/Intrabursal:** Large joints (knee, ankle, shoulder): 5-40 mg (typically 10-20mg). Small joints (fingers, toes): 2.5-10 mg. Frequency: Every 1-8 weeks. **Intralesional:** 1-3 mg per injection site, up to 30 mg total per session. Maximum per site: 0.5-1 mL of 10mg/mL suspension.
Note: For **IM use:** Deep gluteal injection. For **intra-articular use:** Strict aseptic technique. Use appropriate gauge needle (e.g., 21-25G). Aspirate before injection to avoid intravascular administration. Do not inject into the deltoid muscle (risk of subcutaneous atrophy). **SHAKE VIAL WELL** before withdrawing suspension. Do not mix with other injectables. Do not use if clumping or aggregation occurs.
Triamcinolone binds to the cytosolic glucocorticoid receptor (GR), forming a complex that translocates to the nucleus. This complex binds to glucocorticoid response elements (GREs) in DNA, modulating gene transcription. It increases synthesis of anti-inflammatory proteins (lipocortin-1, IL-10) and decreases synthesis of pro-inflammatory mediators (cytokines, chemokines, adhesion molecules, enzymes like COX-2).
Pregnancy: Pregnancy Category C (US FDA). May cause fetal harm. Glucocorticoids cross placenta. Animal studies show teratogenicity (cleft palate). Use only if potential benefit justifies potential fetal risk. Avoid high doses and prolonged use. Monitor neonates for adrenal insufficiency.
Driving: May cause dizziness, vertigo, or visual disturbances. Patients should not drive or operate machinery if affected.
| Warfarin/Anticoagulants | Altered anticoagulant response (increased or decreased INR) | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Increased risk of GI ulceration and bleeding | Major |
| Diuretics (e.g., Furosemide, Hydrochlorothiazide) | Enhanced potassium loss, hypokalemia | Moderate |
| Antidiabetics (Insulin, Metformin) | Antagonizes hypoglycemic effect; increased blood glucose | Major |
| Live Vaccines (MMR, Varicella, OPV) | Reduced antibody response, risk of vaccine-induced infection | Major |
| CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) | Increased metabolism of triamcinolone, reduced efficacy | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | Decreased metabolism of triamcinolone, increased toxicity risk | Moderate |
| Cardiac Glycosides (Digoxin) | Increased risk of digoxin toxicity due to hypokalemia | Moderate |